Literature DB >> 15090755

Posterior leukoencephalopathy and nephrotic syndrome: just a coincidence?

Duygu Yazgan Aksoy1, Mustafa Arici, Ahmet Alper Kiykim, Mine Durusu, Gurdal Sahin, Dilek Ertoy Baydar, Bulent Altun, Yunus Erdem, Unal Yasavul, Cetin Turgan, Sali Caglar.   

Abstract

Posterior leukoencephalopathy syndrome (PLES) is an acute neurological disorder. The most plausible hypothesis for the pathophysiology of PLES is the loss of autoregulation and consequent vasogenic edema. PLES is mostly attributed to severe or sudden elevations of arterial blood pressure. A number of reports, however, describe patients with PLES without severe hypertension. This report presents two patients with nephrotic syndrome who developed PLES without customarily severe hypertension. Proteinuria, low levels of serum albumin, or generalized increase in capillary permeability in nephrotic syndrome can initiate PLES with moderately high arterial blood pressure levels. PLES is increasingly recognized by neurologists, but it should also be remembered by internists when confronted with patients with nephrotic syndrome who present with neurological symptoms, whether or not they have severe hypertension.

Entities:  

Mesh:

Year:  2004        PMID: 15090755     DOI: 10.1097/00000441-200403000-00008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Posterior reversible encephalopathy syndrome in a patient with hepatitis B induced type 1 membranoproliferative glomerulonephritis.

Authors:  Vishwanath Sathyanarayanan; Abdul Razak; Girish Narayan; Mukhyaprana Prabhu; Balasubramanian Ramachandran; Kudva Ranjini; Monappa Vidya; Kusum Joshi
Journal:  Clin Exp Nephrol       Date:  2010-08-21       Impact factor: 2.801

2.  Nephrotic Syndrome and Atypical Posterior Reversible Encephalopathy Syndrome in a Patient with Parkinson's Disease.

Authors:  Ryo Tokimura; Eiichi Ito; Yoshihiro Sugiura; Yoshikazu Ugawa
Journal:  Intern Med       Date:  2021-12-18       Impact factor: 1.282

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.